Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir

A once every eight-week cabotegravir (CAB) long-acting parenteral is more effective than daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human immunodeficiency virus type one (HIV-1) transmission. Extending CAB dosing to a yearly injectable advances efforts for the eliminati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Gautam, Nagsen, McMillan, JoEllyn M., Kumar, Devendra, Bade, Aditya N., Pan, Qiaoyu, Kulkarni, Tanmay A., Li, Wenkuan, Sillman, Brady, Smith, Nathan A., Shetty, Bhagya L. Dyavar, Szlachetka, Adam, Edagwa, Benson J., Gendelman, Howard E., Alnouti, Yazen
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8187380/
https://ncbi.nlm.nih.gov/pubmed/34103484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-23668-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados